Neurotrophic effects of the peptide NAP: a novel neuroprotective drug candidate

Curr Alzheimer Res. 2006 Jul;3(3):197-9. doi: 10.2174/156720506777632790.


This short review outlines the scientific progression from the neuropeptide vasoactive intestinal peptide as a neuroprotective agent that acts through glial cells to increase and modulate the synthesis and secretion of novel neuroprotective substances. Recent development in the studies on activity-dependent neuroprotective protein (ADNP) and activity-dependent neurotrophic factor (ADNF) and short peptide derivatives of these proteins, ADNF-9 and NAP suggest that these peptides are neurotrophic and promote neurite outgrowth. These short peptides hold promise in future neuroprotective/neurotrophic drug development. Clinical development of NAP is currently in progress by Allon Therapeutics, Inc.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Homeodomain Proteins / metabolism*
  • Humans
  • Nerve Growth Factors / metabolism*
  • Nerve Tissue Proteins / metabolism*
  • Neuronal Plasticity / physiology
  • Neurons / metabolism*
  • Neuroprotective Agents / metabolism*
  • Oligopeptides / metabolism*
  • Signal Transduction / physiology
  • Vasoactive Intestinal Peptide / metabolism


  • ADNP protein, human
  • Homeodomain Proteins
  • Nerve Growth Factors
  • Nerve Tissue Proteins
  • Neuroprotective Agents
  • Oligopeptides
  • Vasoactive Intestinal Peptide
  • davunetide